RCAMU
RARE icon

Rothschild & Co Asset Management US’s Ultragenyx Pharmaceutical RARE Stock Holding History

Rothschild & Co Asset Management US’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$6.46M Buy
139,517
+18,850
+16% +$741K 0.1% 159
2022
Q3 		$5M Buy
120,667
+71,494
+145% +$3.67M 0.09% 174
2022
Q2 		$2.93M Buy
49,173
+5,255
+12% +$323K 0.05% 223
2022
Q1 		$3.19M Buy
+43,918
New +$3.06M 0.04% 225
2020
Q3 		– Sell
-125,683
Closed -$9.83M – 315
2020
Q2 		$9.83M Sell
125,683
-16,187
-11% -$1.07M 0.14% 218
2020
Q1 		$6.3M Sell
141,870
-17,313
-11% -$899K 0.1% 240
2019
Q4 		$6.8M Buy
159,183
+51,593
+48% +$2.13M 0.07% 272
2019
Q3 		$4.6M Buy
107,590
+2,315
+2% +$126K 0.05% 284
2019
Q2 		$6.68M Buy
105,275
+49,735
+90% +$3.17M 0.07% 274
2019
Q1 		$3.85M Buy
55,540
+26,899
+94% +$1.54M 0.04% 296
2018
Q4 		$1.25M Sell
28,641
-266
-0.9% -$14.5K 0.02% 342
2018
Q3 		$2.21M Sell
28,907
-360
-1% -$29.3K 0.02% 334
2018
Q2 		$2.25M Buy
29,267
+5,998
+26% +$387K 0.02% 330
2018
Q1 		$1.19M Sell
23,269
-1,907
-8% -$96K 0.01% 339
2017
Q4 		$1.17M Sell
25,176
-1,883
-7% -$92.3K 0.01% 334
2017
Q3 		$1.44M Sell
27,059
-377
-1% -$22.3K 0.02% 318
2017
Q2 		$1.7M Sell
27,436
-1,448
-5% -$87.2K 0.02% 336
2017
Q1 		$1.96M Sell
28,884
-2,120
-7% -$162K 0.02% 322
2016
Q4 		$2.18M Buy
31,004
+25,404
+454% +$1.8M 0.03% 333
2016
Q3 		$397K Buy
5,600
+830
+17% +$53K 0.01% 506
2016
Q2 		$233K Buy
+4,770
New +$309K ﹤0.01% 549

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Rothschild & Co Asset Management US's RARE Position: Q4 2022 in Review

Rothschild & Co Asset Management US increased its Ultragenyx Pharmaceutical (RARE) stake by 16% in Q4 2022, buying an estimated $741K and bringing the position to 139,517 shares worth $6.46M. The position accounts for 0.1% of the portfolio, ranked #159.

Rothschild & Co Asset Management US first reported a position in RARE in Q2 2016 and has held it in 21 quarters since. The position peaked at $9.83M in Q2 2020. 228 funds tracked by Wall St. Rank hold RARE as of Q4 2022.

  • Rothschild & Co Asset Management US held 139,517 shares of Ultragenyx Pharmaceutical worth $6.46M as of Q4 2022.
  • Rothschild & Co Asset Management US bought 18,850 Ultragenyx Pharmaceutical shares in Q4 2022, an estimated $741K.
  • Ultragenyx Pharmaceutical made up 0.1% of Rothschild & Co Asset Management US's portfolio in Q4 2022, its #159 holding.
  • Rothschild & Co Asset Management US first reported a position in Ultragenyx Pharmaceutical in Q2 2016 and has held it in 21 quarters since.
  • Rothschild & Co Asset Management US's Ultragenyx Pharmaceutical position peaked at $9.83M in Q2 2020.
  • 228 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2022.

Based on Rothschild & Co Asset Management US's 13F filing for Q4 2022, filed 14 Feb 2023.